Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Migraine Prevention With the Remote Electrical Neuromodulation (REN) Wearable: A Real-world Evidence Study

NCT: NCT07487701 · COMPLETED

NCT IDNCT07487701
StatusCOMPLETED
Start Date2026-02-20
Completion2026-04-15
SponsorTheranica (INDUSTRY)
First posted
Last updated

Brief Summary

Preventive pharmacologic therapies for migraine aim to reduce attack frequency and duration and improve quality of life; however, their use, overall benefit and adherence are often limited. Remote electrical neuromodulation (REN) is a non-invasive FDA-cleared wearable device for acute and/or preventive migraine treatment. This study will evaluate the real-world efficacy and patient-reported outcomes of preventive REN use over 3 months in migraine patients.

Frequently Asked Questions

What is Migraine Prevention With the Remote Electrical Neuromodulation (REN) Wearable: A Real-world Evidence Study?

Migraine Prevention With the Remote Electrical Neuromodulation (REN) Wearable: A Real-world Evidence Study is a clinical trial registered under NCT07487701. Current status: COMPLETED.

What is the status of NCT07487701?

The current status of NCT07487701 (Migraine Prevention With the Remote Electrical Neuromodulation (REN) Wearable: A Real-world Evidence Study) is: COMPLETED.

When did Migraine Prevention With the Remote Electrical Neuromodulation (REN) Wearable: A Real-world Evidence Study start?

Migraine Prevention With the Remote Electrical Neuromodulation (REN) Wearable: A Real-world Evidence Study started on 2026-02-20.

Related Devices

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.